MiRNA-based therapy for Chronic Myelogenous Leukemia (CML): MiRNA-217 eradicates CML leukemia stem cells via activation of p53, 8/October/2014, 7.03 am

Natural product-based therapy for Human cancer: I3C, a compound found in Broccoli & Brussels, inhibits tumor cell proliferation via down regulation of Superoxide dismutase 1 (SOD1), 8/October/2014, 6.43 am,
October 8, 2014
Small molecule therapy for Myocardial Infarction: Alpha-lipoic acid improves myocardial function after myocardial infarction via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 8/October/2014, 7.13 am
October 8, 2014
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

CitationBoominathan, MiRNA-based therapy for Chronic Myelogenous Leukemia (CML): MiRNA-217 eradicates CML leukemia stem cells via activation of p53, 8/October/2014, 7.03 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Significance: This study suggests that tumor suppressor MiRNA-217, by decreasing the expression of its target gene, it may increase the expression of guardian of the genome p53and decrease the expression of immortality gene telomerase. Given that p53 is the most mutated tumor suppressor gene in human cancer, pharmacological formulations encompassing “MiRNA-217 or its activators may be used to eliminate CML leukemia stem cells.

Comments are closed.